Regulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach

scientific article published on October 2012

Regulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1049075340
P356DOI10.1097/WOX.0B013E318272484E
P932PMC publication ID3651208
P698PubMed publication ID23282336
P5875ResearchGate publication ID234042033

P50authorSergio BoniniQ42220764
P2093author name stringSergio Bonini
P2860cites workClose collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children.Q46020580
The EAMG position on the regulation of existing products for treatment with special reference to named patient products (NPPs).Q52089842
Allergen immunotherapy: a practice parameter third update.Q52712682
The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paperQ61684954
Who benefits from immunotherapy?Q61685029
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) articleQ82636815
Clinical guidelines: developing guidelinesQ33536430
The heterogeneity of allergic phenotypes: genetic and environmental interactionsQ34480417
Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paperQ34754637
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.Q36734980
The regulatory system in europe with special emphasis on allergen productsQ37224227
Comparison of allergen immunotherapy practice patterns in the United States and EuropeQ37677729
Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guidelineQ37770580
Regulatory aspects of specific immunotherapy in EuropeQ37791805
Regulatory environment for allergen-specific immunotherapyQ37834696
New perspective and new challenges in clinical trial regulation in Italy.Q37856610
Allergen immunotherapy practice in the United States: guidelines, measures, and outcomesQ37941117
Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statementQ38010810
Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein componentQ41034495
P433issue10
P921main subjectimmunotherapyQ1427096
P304page(s)120-123
P577publication date2012-10-01
P1433published inThe World Allergy Organization JournalQ15756346
P1476titleRegulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach
P478volume5